BioXcel Therapeutics (BTAI)

• Market cap: $40.4M
• 1 day: 7.38%
• 5 days: 20.18%
• 1 month: 20.18%
• 3 months: -21.56%
• 6 months: -41.78%
• Year to date: -22.94%
• 1 year: -5.76%
• 5 years: -99.76%
• 10 years: -99.26%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Employees: 29